Acrivon Therapeutics, Inc. Common Stock

ACRV · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$18,234-$21,006-$19,680-$22,831
Dep. & Amort.$300$162$311$303
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$3,927$3,791$3,707
Change in WC$1,466$52-$3,845$2,115
Other Non-Cash$4,185$255-$112-$654
Operating Cash Flow-$12,283-$16,610-$19,535-$17,360
Investing Activities
PP&E Inv.-$899-$493-$58-$827
Net Acquisitions$0$0$0$0
Inv. Purchases-$33,190-$15,056-$20,228-$34,761
Inv. Sales/Matur.$40,000$35,000$39,500$50,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$5,911$19,451$19,214$14,412
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$1$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$117-$97-$344-$647
Financing Cash Flow-$117-$97-$343-$647
Forex Effect-$1$0$0$0
Net Chg. in Cash-$6,490$2,744-$664-$3,595
Supplemental Information
Beg. Cash$41,895$39,352$40,016$43,611
End Cash$35,405$42,096$39,352$40,016
Free Cash Flow-$13,182-$17,103-$19,593-$18,187
Acrivon Therapeutics, Inc. Common Stock (ACRV) Financial Statements & Key Stats | AlphaPilot